The US Food and Drug Administration has approved lenacapavir, an injectable form of HIV prevention that is almost 100 percent effective. The medicine works by blocking the virus from reproducing during its early stages. Clinical trials showed it to be 99.9% effective in preventing HIV infection through sexual transmission.
Lenacapavir requires only two doses per year, making it a more manageable option than existing daily medication options like pre-exposure prophylaxis (PrEP) pills. The long-lasting effects of lenacapavir are hoped to make it easier for people to stay protected against the virus.
However, concerns have been raised about access due to high prices. Yeztugo, the trade name for lenacapavir, has an annual list price of $28,218 per person in the US. Gilead Sciences plans to offer the medication in 120 low- and lower-middle-income countries through a voluntary licensing program, which aims to provide affordable access to the treatment.
Source: https://www.wired.com/story/fda-finally-approves-lenacapavir-preventive-hiv-treatment-gilead